Employees of “Neuralink” said that the “Food and Drug Administration” told the company that there are dozens of issues that must be addressed before conducting human tests, which will be a milestone for the final approval of the product.
The department asked, according to the same sources, to address the main safety concerns of the lithium batteries used, and whether the chip could be removed without damaging brain tissue.
The US authority’s concerns include safety aspects that include the seriousness of the built-in lithium battery, as it indicated the necessity of conducting animal tests to prove that the battery is not subject to malfunction and cannot damage brain tissue.
The authority’s decision comes to delay human experimentation, after Musk said last December that he intends to perform the first chip implantation in a human brain in the next 6 months, with the aim of helping people suffering from paralysis to regain movement.
